New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday,...
Related Questions
How does the enrollment progress in the NEPHRO study compare to the company's original timeline and expected milestones?
What is the expected impact of the $6.8âŻmillion cash position on the company's burn rate and runway through the end of 2025?
Are there any upcoming regulatory milestones or data readouts from the NEPHRO study that could act as catalysts for the stock?
How does the secondâquarter revenue and earnings (or loss) compare to consensus estimates and prior quarters?
What guidance did management provide for Q3 and fullâyear 2025 financial performance, and how does it align with analyst expectations?
Did the company announce any partnership, licensing, or financing arrangements that could affect future cash flow or valuation?
What are the implications of the new site openings on patient enrollment speed and overall trial timelines?
How does TRIAâs valuation metrics (e.g., P/E, EV/EBITDA) look after this earnings release relative to peers in the nephrology biotech space?
What is the marketâs reaction to the conference call, and are there any redâflag comments from management regarding risks or delays?
How might the sentiment score of 35 influence shortâterm trader sentiment and volatility in the stock?